相似文献
1
AJRCCM: 100-Year Anniversary. Progress along the Pathway of Discovery Leading to Treatment and Cure of Cystic Fibrosis.
Am J Respir Crit Care Med. 2017 May 1;195(9):1092-1099. doi: 10.1164/rccm.201702-0266ED.
2
Treating Specific Variants Causing Cystic Fibrosis.
JAMA. 2017 Dec 5;318(21):2130-2131. doi: 10.1001/jama.2017.16823.
3
A combination therapy for cystic fibrosis.
Cell. 2015 Sep 24;163(1):17. doi: 10.1016/j.cell.2015.09.003.
4
Clinical trial research in focus: ensuring new cystic fibrosis drugs fulfil their potential.
Lancet Respir Med. 2017 Sep;5(9):681-683. doi: 10.1016/S2213-2600(17)30311-9.
5
Cystic Fibrosis: The Dawn of a New Therapeutic Era.
Am J Respir Crit Care Med. 2017 Apr 15;195(8):979-984. doi: 10.1164/rccm.201606-1250PP.
6
Lumacaftor/ivacaftor combination therapy for cystic fibrosis: A nationwide survey among clinicians.
Clin Respir J. 2018 Apr;12(4):1767-1768. doi: 10.1111/crj.12677. Epub 2017 Aug 4.
7
The march towards CFTR modulator access for all people with CF: The end of the beginning.
J Cyst Fibros. 2021 Mar;20(2):185-187. doi: 10.1016/j.jcf.2021.01.005. Epub 2021 Jan 22.
8
New Therapeutic Approaches to Modulate and Correct Cystic Fibrosis Transmembrane Conductance Regulator.
Pediatr Clin North Am. 2016 Aug;63(4):751-64. doi: 10.1016/j.pcl.2016.04.006.
9
[Causal therapy is available].
MMW Fortschr Med. 2016 Jun 23;158(12):74. doi: 10.1007/s15006-016-8458-8.
10
Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm?
Thorax. 2015 Jul;70(7):615-6. doi: 10.1136/thoraxjnl-2015-207369.
引用本文的文献
1
Normalization of Cystic Fibrosis Immune System Reverses Intestinal Neutrophilic Inflammation and Significantly Improves the Survival of Cystic Fibrosis Mice.
Cell Mol Gastroenterol Hepatol. 2025;19(2):101424. doi: 10.1016/j.jcmgh.2024.101424. Epub 2024 Nov 6.
2
Loss of CFTR function in macrophages alters the cell transcriptional program and delays lung resolution of inflammation.
Front Immunol. 2023 Nov 16;14:1242381. doi: 10.3389/fimmu.2023.1242381. eCollection 2023.
3
Aberrant immune programming in neutrophils in cystic fibrosis.
J Leukoc Biol. 2024 Feb 23;115(3):420-434. doi: 10.1093/jleuko/qiad139.
4
Effects of lumacaftor-ivacaftor therapy on cystic fibrosis transmembrane conductance regulator function in F508del homozygous patients with cystic fibrosis aged 2-11 years.
Front Pharmacol. 2023 May 30;14:1188051. doi: 10.3389/fphar.2023.1188051. eCollection 2023.
5
Cftr deletion in mouse epithelial and immune cells differentially influence the intestinal microbiota.
Commun Biol. 2022 Oct 26;5(1):1130. doi: 10.1038/s42003-022-04101-5.
6
Journey on VX-809-Based Hybrid Derivatives towards Drug-like F508del-CFTR Correctors: From Molecular Modeling to Chemical Synthesis and Biological Assays.
Pharmaceuticals (Basel). 2022 Feb 23;15(3):274. doi: 10.3390/ph15030274.
7
A small molecule CFTR potentiator restores ATP-dependent channel gating to the cystic fibrosis mutant G551D-CFTR.
Br J Pharmacol. 2022 Apr;179(7):1319-1337. doi: 10.1111/bph.15709. Epub 2022 Jan 21.
8
CFTR Modulator Therapy with Lumacaftor/Ivacaftor Alters Plasma Concentrations of Lipid-Soluble Vitamins A and E in Patients with Cystic Fibrosis.
Antioxidants (Basel). 2021 Mar 19;10(3):483. doi: 10.3390/antiox10030483.
9
Educational Needs and Preferences for Patient-Centered Outcomes Research in the Cystic Fibrosis Community: Mixed Methods Study.
JMIR Form Res. 2021 Mar 4;5(3):e24302. doi: 10.2196/24302.
10
The Pathophysiology of Rett Syndrome With a Focus on Breathing Dysfunctions.
Physiology (Bethesda). 2020 Nov 1;35(6):375-390. doi: 10.1152/physiol.00008.2020.
本文引用的文献
1
Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation.
J Pediatr. 2017 Feb;181S:S4-S15.e1. doi: 10.1016/j.jpeds.2016.09.064.
2
New horizons for cystic fibrosis treatment.
Pharmacol Ther. 2017 Feb;170:205-211. doi: 10.1016/j.pharmthera.2016.11.009. Epub 2016 Dec 1.
3
Atomic Structure of the Cystic Fibrosis Transmembrane Conductance Regulator.
Cell. 2016 Dec 1;167(6):1586-1597.e9. doi: 10.1016/j.cell.2016.11.014.
4
Early Lung Disease in Infants and Preschool Children with Cystic Fibrosis. What Have We Learned and What Should We Do about It?
Am J Respir Crit Care Med. 2017 Jun 15;195(12):1567-1575. doi: 10.1164/rccm.201606-1107CI.
5
Lumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for F508del-CFTR.
Ann Am Thorac Soc. 2017 Feb;14(2):213-219. doi: 10.1513/AnnalsATS.201609-689OC.
6
Architecture and functional properties of the CFTR channel pore.
Cell Mol Life Sci. 2017 Jan;74(1):67-83. doi: 10.1007/s00018-016-2389-5. Epub 2016 Oct 3.
7
Genetic medicines for CF: Hype versus reality.
Pediatr Pulmonol. 2016 Oct;51(S44):S5-S17. doi: 10.1002/ppul.23543.
8
Discovery of Clinically Approved Agents That Promote Suppression of Cystic Fibrosis Transmembrane Conductance Regulator Nonsense Mutations.
Am J Respir Crit Care Med. 2016 Nov 1;194(9):1092-1103. doi: 10.1164/rccm.201601-0154OC.
9
Airway acidification initiates host defense abnormalities in cystic fibrosis mice.
Science. 2016 Jan 29;351(6272):503-7. doi: 10.1126/science.aad5589.
10
From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations.
Mol Biol Cell. 2016 Feb 1;27(3):424-33. doi: 10.1091/mbc.E14-04-0935.
Zotero 插件